Clinical trials

Condition   Drug Name  
Study Voclosporin in psoriasis
Design Randomized; Double-blind
Patients 451
Treatment Regimen Voclosporin, 0.2 mg/kg b.i.d. x 24 wks --> 0.3 mg/kg b.i.d. 36 wks; Voclosporin, 0.3 mg/kg b.i.d. x 60 wks; Voclosporin, 0.4 mg/kg b.i.d. x 24 wks --> 0.3 mg/kg b.i.d. 36 wks; Placebo x 12 wks --> Voclosporin, 0.3 mg/kg b.i.d. x 48 wks
Conclusions Voclosporin demonstrated sustained efficacy and tolerability in patients with plaque psoriasis
Reference(s) ISA247: Continued safety and efficacy after 60 weeks of continuous therapy in plaque psoriasis by SGA
16th Congr Eur Acad Dermatol Venereol (EADV) (May 16 2007 , Vienna) 2007:Abst P206.
Author and Affiliation Papp, K., Rosoph, L., Wasel, N., et al.